Click here to read the complete article.
Abstract Title:The impact of Astragaloside IV on the inflammatory response and gut microbiota in cases of acute通过利用PI3K/AKT/MTOR途径来检查肺损伤。
摘要来源：
plos One。 2024; 19（7）：E0305058。 EPUB 2024年7月2日。PMID： 38954702“> 38954702 Lv, Wanzhao Zuo, Yi Yang, Cheng Jiang, Jia Ke
Article Affiliation:Cheng Luo
Abstract:OBJECTIVES: Astragaloside IV (AS-IV) is a natural triterpenoid saponin compound with a variety of pharmacological effects, and several研究已经阐明了其抗炎作用，这可能使其成为针对炎症的有效替代治疗方法。我n the study, we aimed to investigate whether AS-IV could attenuate the inflammatory response to acute lung injury and its mechanisms.
METHODS: Different doses of AS-IV (20mg·kg-1, 40mg·kg-1, and 80mg·kg-1) were administered to the ALI rat model,然后收集血清和支气管肺泡灌洗液（BALF），以检查炎症反应，并通过定量实时PCR（QRT-PCR），Western Blotting（WB）来解释肺和结肠组织的染色，并解释潜在的分子机制。此外，收集了来自Ali大鼠的粪便样品并通过16S rRNA测序分析。
结果： as-iv降低了TNF-α，IL-6，IL-1βIn和balf的水平。肺和结肠组织病理学证实，AS-IV减轻了炎症性浸润，组织水肿和结构变化。 QRT-PCR和WB showed that AS-IV mainly improved inflammation by inhibiting the expression of PI3K, AKT and mTOR mRNA, and improved the disorder of intestinal microflora by increasing the number of beneficial bacteria and reducing the number of harmful bacteria.
CONCLUSION: AS-IV reduces the expression通过抑制PI3K/AKT/MTOR途径并优化肠道大鼠肠道菌群的组成来实现炎症因子。